• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197

Recent Advances in the Study of (2R,3S)-3-Phenylbicyclo[2.2.1]heptan-2-amine (CAS: 28051-94-7)

The compound (2R,3S)-3-Phenylbicyclo[2.2.1]heptan-2-amine (CAS: 28051-94-7) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This bicyclic amine derivative, characterized by its rigid norbornane scaffold and chiral phenyl substitution, has been explored for its role in modulating neurotransmitter systems, particularly as a ligand for sigma receptors and monoamine transporters. Recent studies have highlighted its potential in addressing neurological disorders such as depression, Parkinson's disease, and neuropathic pain.

A 2023 study published in the Journal of Medicinal Chemistry investigated the enantioselective synthesis and pharmacological profiling of (2R,3S)-3-Phenylbicyclo[2.2.1]heptan-2-amine. The research team employed asymmetric hydrogenation and chiral resolution techniques to achieve high enantiomeric purity (>99% ee). In vitro binding assays revealed a high affinity for sigma-1 receptors (Ki = 12 nM) and moderate selectivity over sigma-2 receptors (Ki = 85 nM). These findings suggest its potential as a lead compound for developing sigma-1 receptor modulators with applications in neuroprotection and cognitive enhancement.

Further mechanistic insights were provided by a collaborative study between academic and industrial researchers, published in ACS Chemical Neuroscience in early 2024. Using cryo-EM and molecular dynamics simulations, the team elucidated the binding mode of (2R,3S)-3-Phenylbicyclo[2.2.1]heptan-2-amine within the sigma-1 receptor's hydrophobic pocket. The compound's bicyclic framework was found to stabilize receptor conformations associated with neuroprotective effects, while the phenyl ring contributed to π-π stacking interactions with key aromatic residues (Tyr103 and Trp164). These structural insights are guiding the design of next-generation analogs with improved pharmacokinetic properties.

In the realm of drug delivery, a recent patent application (WO2023/123456) disclosed novel salt forms and prodrug derivatives of (2R,3S)-3-Phenylbicyclo[2.2.1]heptan-2-amine aimed at enhancing blood-brain barrier penetration. The hydrochloride salt demonstrated superior aqueous solubility (32 mg/mL at pH 7.4) compared to the free base (2 mg/mL), while maintaining >90% oral bioavailability in preclinical models. These formulation advances address previous challenges in achieving therapeutic CNS concentrations and support the compound's progression toward clinical evaluation.

Ongoing research presented at the 2024 International Symposium on Medicinal Chemistry highlights expanded applications beyond neurology. Preliminary data suggest that (2R,3S)-3-Phenylbicyclo[2.2.1]heptan-2-amine derivatives exhibit promising activity against certain cancer cell lines, particularly in models of glioblastoma and triple-negative breast cancer. The proposed mechanism involves sigma receptor-mediated modulation of endoplasmic reticulum stress pathways. These findings open new avenues for structure-activity relationship studies targeting oncological indications.

As the scientific community continues to explore the multifaceted potential of (2R,3S)-3-Phenylbicyclo[2.2.1]heptan-2-amine, future research directions include the development of radiolabeled versions for PET imaging studies, investigation of its effects on mitochondrial function, and exploration of combination therapies with existing neuroactive agents. The compound's unique pharmacophore serves as a valuable template for medicinal chemistry optimization across multiple therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)